InfuSystem Holdings (INFU) AI Stock Analysis

• Market Cap: $127.95M
• Dividend Yield: N/A
• Average Volume (3M): 151.59K
• Price to Earnings (P/E): 40.4
• Beta (1Y): 1.34
• Revenue Growth: 7.98%
• EPS Growth: 3304.55%
• Country: US
• Employees: 502
• Sector: Healthcare
• Sector Strength: 41
• Industry: Medical - Instruments & Supplies
• EPS (TTM): -0.01
• Shares Outstanding: 20,975,264
• 10 Day Avg. Volume: 162,894
• 30 Day Avg. Volume: 151,593
• PEG Ratio: 0.84
• Price to Book (P/B): 1.99
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 7.63
• Enterprise Value/Market Cap: 1.10
• Enterprise Value/Revenue: 0.27
• Enterprise Value/Gross Profit: 2.03
• Enterprise Value/Ebitda: 2.15
• 1Y Price Target: $13.17
• Price Target Upside: 115.55% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4

• Rating: 71 Outperform
• Price Target: $6.00 ▼(-1.80%Downside)

InfuSystem Holdings scores well due to strong financial performance and a positive earnings call, indicating robust growth and profitability improvements. While technical analysis points to mixed momentum, and the stock appears overvalued based on P/E ratio, the overall outlook is positive with notable potential for continued growth.

Positive Factors

Financial Performance

The Company showed notable progress in gross margin improvement of 122 basis points Y/Y and AEBITDA margin improvement of 282 basis points Y/Y.

Operating Cash Flow

Operating cash flow was $20.5M in 2024, an 82% increase Y/Y.

Negative Factors

Earnings

EPS of $0.04 was below our estimate and consensus of $0.08 and $0.09, respectively.

Revenue

Revenue came in below our forecast and consensus due to delays in onboarding new wound care initiatives as the Company looks to improve referral processes with newer partners.

InfuSystem Holdings Business Overview & Revenue Model

Company Description

InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Integrated Therapy Services (ITS) and Durable Medical Equipment Services (DME Services). It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. The company also sells, rents, and leases new and pre-owned pole-mounted and ambulatory infusion pumps, and other durable medical equipment; sells treatment-related consumables; and provides biomedical recertification, maintenance, and repair services for oncology practices, as well as other alternate site settings comprising home care and home infusion providers, skilled nursing facilities, pain centers, hospital market, and others. In addition, it offers local and field-based customer support, as well as operates pump service and repair centers. The company was incorporated in 2005 and is headquartered in Rochester Hills, Michigan.

How the Company Makes Money

InfuSystem makes money primarily through a rental and service model for its infusion pumps. The company generates revenue by renting out its extensive inventory of infusion pumps to healthcare providers, such as hospitals and clinics, which prefer not to invest in owning the equipment outright. Additionally, InfuSystem provides repair and maintenance services for these pumps, offering service contracts that ensure equipment is kept in optimal working condition. Another significant revenue stream comes from the sale of disposable medical supplies used in conjunction with the infusion pumps. InfuSystem’s earnings are further bolstered by partnerships with healthcare facilities, which often result in long-term contracts and recurring revenue. These partnerships, along with the company's focus on customer service and quality assurance, contribute significantly to its financial success.

InfuSystem Holdings Financial Statement Overview

Summary

InfuSystem Holdings, Inc. shows strong financial health with impressive revenue growth and improved profitability margins. The balance sheet reflects better leverage management and a strong equity position. Cash flow performance is excellent, with significant growth in free cash flow, despite the company's historical high debt levels requiring cautious management.

Income Statement

InfuSystem Holdings, Inc. has shown a solid revenue growth rate of 7.22% from 2023 to 2024, and their gross profit margin is strong at approximately 52.17%. The company has improved its net profit margin significantly from 0.69% in 2023 to 5.76% in 2024. The EBIT and EBITDA margins have also improved, indicating better operational efficiency. However, the past volatility in net income suggests that profitability has been inconsistent over the years.

Balance Sheet

The company's debt-to-equity ratio has decreased from 0.70 in 2023 to 0.08 in 2024, showing improved leverage. The equity ratio is stable at 55.53%, indicating a strong equity position relative to assets. Return on equity has improved to 13.51% in 2024, showcasing better returns for shareholders. However, historical high debt levels pose a potential risk if not managed carefully.

Cash Flow

InfuSystem Holdings, Inc. has demonstrated impressive free cash flow growth, from $106,000 in 2023 to $19.37 million in 2024. The operating cash flow to net income ratio is strong, indicating efficient cash generation relative to profits. The free cash flow to net income ratio also shows a robust ability to generate cash, enhancing financial flexibility. Despite previous fluctuations, current cash flow management appears solid.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
134.86M	125.78M	109.91M	102.38M	97.39M
	Gross Profit
70.40M	63.11M	62.57M	60.20M	58.76M
	EBIT
6.89M	4.09M	1.65M	2.82M	8.83M
	EBITDA
20.03M	16.50M	15.09M	17.15M	22.82M
	Net Income Common Stockholders
2.35M	872.00K	18.00K	1.42M	17.33M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
527.00K	231.00K	165.00K	186.00K	9.65M
	Total Assets
103.61M	102.92M	99.39M	97.59M	96.99M
	Total Debt
28.42M	36.37M	36.92M	36.77M	42.66M
	Net Debt
27.90M	36.14M	36.75M	36.58M	33.02M
	Total Liabilities
46.09M	50.61M	51.38M	49.31M	56.24M
	Stockholders Equity
57.53M	52.30M	48.00M	48.27M	40.75M
Cash Flow		Free Cash Flow
2.63M	106.00K	2.44M	1.66M	3.37M
	Operating Cash Flow
20.46M	11.22M	17.52M	18.32M	20.28M
	Investing Cash Flow
-13.24M	-6.73M	-11.48M	-21.32M	-12.16M
	Financing Cash Flow
-6.92M	-4.42M	-6.06M	-6.46M	-1.12M

InfuSystem Holdings Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 6.11
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For INFU, the sentiment is Neutral. The current price of 6.11 is above the 20-day moving average (MA) of 5.78, above the 50-day MA of 5.33, and below the 200-day MA of 6.88, indicating a neutral trend. The MACD of 0.17 indicates Negative momentum. The RSI at 60.52 is Neutral, neither overbought nor oversold. The STOCH value of 87.09 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for INFU.

InfuSystem Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
INFU	71 Outperform	$127.95M	40.40	5.94%	―	7.98%	3304.55%
UTMD	67 Neutral	$181.67M	14.84	10.59%	2.16%	-19.92%	―
STXS	64 Neutral	$192.64M	―	-179.82%	―	1.50%	-20.00%
KRMD	61 Neutral	$134.73M	―	-29.87%	―	19.65%	60.28%
MLSS	54 Neutral	$71.38M	―	-88.36%	―	-9.13%	30.04%
Sector *	54 Neutral	$5.24B	3.27	-45.39%	2.80%	16.77%	-0.07%
SMTI	50 Neutral	$256.68M	―	-28.58%	―	34.65%	-128.56%

InfuSystem Holdings Corporate Events

InfuSystem Holdings Announces New CEO Employment Agreement

InfuSystem Holdings, Inc. announced a Second Amended and Restated Employment Agreement with its President and CEO, Carrie Lachance, reflecting her transition from COO to CEO on May 19, 2025. The agreement includes changes in compensation, stock options, and performance-based incentives, along with severance benefits and confidentiality provisions. Additionally, on May 15, 2025, the company’s stockholders approved Charter Amendments to its Certificate of Incorporation, removing outdated provisions and designating exclusive forums for certain claims.

The most recent analyst rating on (INFU) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on InfuSystem Holdings stock, see the INFU Stock Forecast page.

InfuSystem Holdings Approves Equity Plan Amendment, New Chairman

At the 2025 Annual Meeting of Stockholders held on May 15, 2025, InfuSystem Holdings, Inc. announced the approval of the Second Amendment to its 2021 Equity Incentive Plan, increasing the maximum number of shares reserved for issuance to 6,000,000. This amendment, along with other approved proposals, aims to enhance the company’s operational flexibility and governance structure. Additionally, Ronald Hundzinski was elected as the Chairman of the Board of Directors, reflecting a shift in leadership dynamics. The meeting also saw the approval of several amendments to the company’s Certificate of Incorporation, including changes to forum selection for stockholder actions and officer exculpation, as well as the ratification of Deloitte & Touche LLP as the independent accounting firm for 2025.

The most recent analyst rating on (INFU) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on InfuSystem Holdings stock, see the INFU Stock Forecast page.

InfuSystem Holdings Reports Record 2024 Revenue Growth

InfuSystem Holdings announced its financial performance for 2024, reporting a record revenue of $134.9 million, marking six consecutive years of revenue growth with a compound annual growth rate (CAGR) of 12%. The company also highlighted its strong balance sheet and substantial annual cash flow, positioning it well for future growth. InfuSystem’s strategic initiatives include expanding its device solutions and patient services, with a focus on oncology, pain management, and wound care. The company has established significant partnerships and distribution agreements, enhancing its market presence and service capabilities.

InfuSystem Holdings to Announce Q1 2025 Results

InfuSystem Holdings, Inc. announced that it will release its first quarter 2025 financial results on May 8, 2025, before the market opens. The company will also host a conference call on the same day to discuss the results, providing stakeholders an opportunity to gain insights into the company’s financial performance and strategic direction.

InfuSystem Holdings Announces CEO Transition in 2025

On April 1, 2025, InfuSystem Holdings, Inc. announced the upcoming departure of CEO Richard A. DiIorio, effective May 19, 2025, with Carrie Lachance set to succeed him. Lachance, who has been with the company since 2010 and served in various leadership roles, is expected to lead the company into its next growth phase. The transition is part of a planned succession, with DiIorio remaining as an advisor during the transition. The company reaffirmed its 2025 financial guidance, projecting revenue growth of 8-10% and an adjusted EBITDA margin exceeding 18.8%, indicating continued confidence in its operational performance despite ongoing investments.